Biotechnology
Karyopharm Files Chapter 11 and Plans Merger With Ayrmid
Karyopharm Therapeutics announced on November 2, 2026 that it has entered into a Restructuring Support Agreement with its existing lenders and noteholders and other key stakeholders, providing for a merger between Ayrmid Ltd. and a reorganized Karyopharm. To implement the…
InventisBio Nomelcitinib Meets Phase III Endpoints in Plaque Psoriasis
InventisBio Co., Ltd. announced topline results on November 2, 2026, from a registrational Phase III trial of its oral JH2 selective TYK2 inhibitor nomelcitinib (D-2570) in patients with moderate-to-severe plaque psoriasis. The company said the study met both its primary…
Fresenius Signs WuXi Biologics Pact for Up to 37 Biosimilar Candidates
Fresenius SE & Co. KGaA announced on November 2, 2026, that it has entered an exclusive development agreement with WuXi Biologics, a global contract research, development and manufacturing organization, giving Fresenius exclusive access to up to 37 identified biosimilar candidates…
INOVIO’s VOCERYQ Wins FDA Accelerated Approval to Reduce RRP Surgeries
INOVIO announced on October 30, 2026 that the U.S. Food and Drug Administration granted accelerated approval for VOCERYQ (doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd), previously referred to as INO-3107, to reduce the frequency of surgery in adults with recurrent respiratory papillomatosis…
Azenta Acquires SynPlexity and Licenses Elegen DNA Technology
Azenta, Inc. announced on October 30, 2026, two strategic investments intended to advance the next phase of growth for its GENEWIZ business: an exclusive licensing agreement with Elegen Corp., a developer of advanced cell-free DNA manufacturing technology, and the acquisition…
Sun Pharma Wins FDA Approval for Ilumya in Active Psoriatic Arthritis
Sun Pharmaceutical Industries announced on October 30, 2026 that the U.S. Food and Drug Administration approved the supplemental Biologics License Application for Ilumya (tildrakizumab-asmn) for the treatment of adults with active psoriatic arthritis. The approval, set out in the company’s…
Cambrex Starts Construction on $120 Million Iowa API Expansion
Cambrex, a contract development and manufacturing organization based in East Rutherford, New Jersey, announced on October 30, 2026 the groundbreaking of a $120 million expansion at its Charles City, Iowa manufacturing facility. The company said the project will add 160,000…
PTC Therapeutics Raises 2026 Outlook as Q3 Revenue Hits $358 Million
PTC Therapeutics reported financial results for the third quarter ended September 30, 2026, on October 29, 2026, posting total revenues of $357.8 million and raising its full-year 2026 total revenue expectation to a range of $1.29 billion to $1.32 billion.…
Illumina Raises 2026 Guidance as Q3 Revenue Climbs to $1.13 Billion
Illumina on October 29, 2026, reported revenue of $1.13 billion for the third quarter of fiscal 2026, up 4.2% from $1,084 million a year earlier, and raised its full-year revenue and earnings guidance. The company reported GAAP diluted earnings per…
Biohaven Q3 Loss Narrows as FDA Accepts Vyglxia NDA Resubmission
Biohaven Ltd. on October 29, 2026, reported a net loss of $129.3 million, or $0.86 per share, for the third quarter ended September 30, 2026, compared with a net loss of $173.4 million, or $1.64 per share, in the same…
BioMarin Licenses Fabry Disease Therapy From GC Biopharma and Hanmi
BioMarin Pharmaceutical Inc. on October 29, 2026 announced an exclusive worldwide license agreement with GC Biopharma Corp. and Hanmi Pharm Co., Ltd. to develop and commercialize HM15421/GC1134A, an investigational long-acting enzyme replacement therapy for Fabry disease. Under the terms of…
Viking Therapeutics Q3 Net Loss Widens to $183.2 Million
Viking Therapeutics on October 28, 2026, reported its financial results for the third quarter and nine months ended September 30, 2026, posting a net loss of $183.2 million, or $1.55 per share, for the quarter, compared with a net loss…
Lilly Retatrutide Beats Ozempic on A1C and Weight Loss in Phase 3 Trial
Eli Lilly and Company , the maker of Mounjaro (tirzepatide) and Foundayo (orforglipron), on October 28, 2026, announced positive topline results from TRANSCEND-T2D-2, a head-to-head Phase 3 trial comparing retatrutide with injectable Ozempic 2 mg in adults with type 2…
Leqembi Q3 Sales Total 32.2 Billion Yen as BioArctic Royalty Rises 74%
BioArctic AB said on October 28, 2026 that its partner Eisai published preliminary global revenue for the Alzheimer’s disease treatment Leqembi (lecanemab) totaling 32.2 billion Japanese yen in the third quarter of 2026. The figure, released in conjunction with partner…
Amgen Discloses Phase 3 Sjögren’s Data Ahead of ACR Convergence 2026
Amgen on October 27, 2026 announced plans to present new data across its portfolio in rare and other serious autoimmune diseases at the American College of Rheumatology (ACR) Convergence 2026, led by late-breaking results from the Phase 3 OASIZ-301 study…
